Baxter International Inc.’s Stock Price Soars to $35.08, Boasting a Robust 3.73% Increase

Baxter International Inc. (BAX)

35.08 USD +1.26 (+3.73%) Volume: 7.7M

Baxter International Inc.’s stock price is currently at 35.08 USD, indicating a positive trading session with a percentage increase of +3.73%. With a significant trading volume of 7.7M and a year-to-date percentage increase of +20.30%, BAX demonstrates a robust stock performance in the market.

Latest developments on Baxter International Inc.

Baxter International (NYSE:BAX) recently made headlines with the announcement of CEO José E. Almeida’s retirement and the appointment of Brent Shafer as interim CEO. The company also reported strong financial performance in 2024, leading to an upgraded stock rating by Argus. Despite a dividend payout of $0.17, some analysts question the wisdom of buying Baxter International stock at this time. However, Handelsbanken Fonder AB and New York State Common Retirement Fund seem confident in the company’s future, increasing their shares. With a resilient Q4 2024 and a positive outlook for 2025, Baxter International continues to attract investor interest, despite a recent price target cut by JPMorgan Chase & Co.

A look at Baxter International Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on Smartkarma Smart Scores, Baxter International has a positive long-term outlook. With high scores in Dividend and Value, the company is seen as stable and offering good returns to investors. However, lower scores in Growth and Resilience indicate some challenges in terms of expanding and withstanding market pressures. Momentum is moderate, suggesting a steady performance in the near future.

Baxter International Inc. is a company that specializes in developing and manufacturing medical products for various medical conditions. Their products are widely used in healthcare facilities such as hospitals, dialysis centers, and doctors’ offices. Despite some areas of improvement highlighted by the Smart Scores, Baxter International remains a key player in the medical industry, providing essential products for patients worldwide.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma